1. Home
  2. ORLA vs APGE Comparison

ORLA vs APGE Comparison

Compare ORLA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orla Mining Ltd.

ORLA

Orla Mining Ltd.

HOLD

Current Price

$13.39

Market Cap

4.5B

ML Signal

HOLD

Logo Apogee Therapeutics Inc.

APGE

Apogee Therapeutics Inc.

HOLD

Current Price

$81.94

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORLA
APGE
Founded
2007
2022
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.7B
IPO Year
2016
2023

Fundamental Metrics

Financial Performance
Metric
ORLA
APGE
Price
$13.39
$81.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
13
Target Price
$21.00
$109.67
AVG Volume (30 Days)
3.1M
695.9K
Earning Date
05-08-2026
05-12-2026
Dividend Yield
0.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$63.44
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$107.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.16
$34.34
52 Week High
$21.98
$95.32

Technical Indicators

Market Signals
Indicator
ORLA
APGE
Relative Strength Index (RSI) 47.05 47.84
Support Level $12.53 $80.52
Resistance Level $14.14 $86.42
Average True Range (ATR) 0.76 4.54
MACD 0.02 -0.34
Stochastic Oscillator 42.27 44.24

Price Performance

Historical Comparison
ORLA
APGE

About ORLA Orla Mining Ltd.

Orla Mining Ltd is a mineral exploration company. It is engaged in the acquisition and exploration of mineral properties. The company holds three gold projects: the Camino Rojo gold and silver project in Zacatecas State, the Musselwhite gold mine project located in Ontario and the South Railroad projects in Nevada, USA, and the Cerro Quema gold project in Panama. It conducts business activities in Mexico, Panama, the United States, and Canada.

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Share on Social Networks: